Fingolimod hydrochloride Chemical Properties

Melting point 102-107°C

storage temp. -20°C Freezer

solubility water: soluble10mg/mL, clear

color white to beige

CAS DataBase Reference 162359-56-0(CAS DataBase Reference)

Safety Information

Hazard Codes Xi

Risk Statements 36/37/38-52/53

Safety Statements 26-61

MSDS Information

Fingolimod hydrochloride Usage And Synthesis

Oral drug for the treatment of multiple sclerosis Fingolimod hydrochloride is the first oral drug for the treatment of multiple sclerosis. It is successfully developed by the pharmaceutical company Novartis, and it has been approved for marketing by the US Food and Drug Administration (FDA). The recommended dose is 0.5mg once a day for oral administration. 

Multiple sclerosis is a debilitating neurological disease that can cause the patient to lose a sense of balance, appear muscle spasms and other movement disorders. The disease has been treated with injectable drugs. This kind of medication brought great inconvenience to patients. 

Fingolimod is a sphingosine-l-phosphate (S1PR) receptor modulator. After phosphorylation, It is bound to s1P receptor that is on the surface of lymphocyte, which will change lymphocyte migration, and promote cells into the lymphatic tissue, and prevent lymphocytes from leaving the lymphoid tissue and get into the graft. Thereby, it will prevent these cells from infiltrating the central nervous system (CNS), which achieves the effect of immunosuppression. According to the drug's introduction, drugmaker Novartis said that this process of pharmacological effects is reversible. If medication is stopped, the level of lymphocytes in circulating system will return to normal. 

The above information is edited by the chemicalbook of Kui Ming.

Chemical Properties White Solid